ALMS Alumis Inc.

$ALMS got you 30%, saved you 26%, now back in. Everytime i leave a board, stock craters. When i visit the board, I bring profits. Welcome me with open arms.

$ALMS I do not undersatnd why the market thinks ALMS is pricing as a nothing company. the failed Lupus trial is the second indication. the first indication is plaque psoriasis, which is a success in 3 phase 3 trials and 2 phase 2 trials. this is almost guaranteed an approval, with annual peak sales much larger than the current market cap. People are thinking they have a failed drug. it is not true. they have a successful drug, and this drug failed for a secondary indication. it may not be the big one-pill platform for multiple indications as the company wanted, but it is still a successful drug.

$ALMS I bought 909 at $11.00 and 1020 at $9.80. Will continue to buy an additional $10,000 for every $1.00 drop. No debt, 92% institutional ownership, and small short interest. I agree with Oppenheimer on this one. It will bounce back: "Alumis' Share Price Fall After Envudeucitinib Trial Data Likely Overreaction, Oppenheimer Says"

$ALMS has new Phase 3 data showing rapid, durable scalp clearance and itch relief for psoriasis, keeping NDA filing on track for Q4 2026.

$ALMS ⏳🧠👈🏻🧘🏻 .. envudeucitinib has already demonstrated strong efficacy, and in the long-term ONWARD3 study, 54% of patients achieved PASI 100 after 48 weeks. ⬇️⬇️⬇️

$ALMS the short thesis on this is now dead after the bullish confirmation from the company on phase 3 results. Tax loss sellers from the largest volume first week after the big drop are now eligible to buy back after the wash sale window, with more and more eligible every day. The 6.6x bottoming range held and bounced, the big boys have a green light to accumulate now.

$ALMS the simplest explanation for why the stock would continue dropping so much after the large insider purchase is that it means there’s likely no major news - such as an acquisition - currently in the works, even though it is obviously bullish longer term by showing major confidence in the company’s prospects. So the short term speculators have been exiting at these ridiculous rock bottom prices even while it’s clearly oversold. I think large investors will be accumulating at these levels when they see that selling is finally over and this can rocket higher again after the short term specs have all exited at a loss.

$ALMS The Positive Impact: Higher Interest IncomeBecause Alumis does not have any debt to service, they completely bypass the primary risk of a rate hike (rising interest expenses). Instead, they benefit on the asset side of their balance sheet:

$ALMS I thought about it - the only possible reason that the stock is dropping like this, could be that they actually over spent their cash, and they need to seek funding soon. with their cash level, they could not afford to fund the commercial of psoriasis drug alone. and they could not fund the phase 3 lupus subpopulation patients. so the potential buyers or partners are squeezing them with tough negotiations. next earnings we may see how much cash they actually have left.

$ALMS Promising and reassuring presentation at Morgan Stanley 24th Annual Healthcare Conference plus insiders buying up shares… Buying the turnaround!! Bullish with a conservative PT of $15 by end of Sept!

$ALMS cannot believe Otezla generates roughly $2.1 billion to $2.3 billion in annual revenue for Amgen. According to Amgen’s official financial reports, its recent full-year global sales figures are: • 2025: $2.27 billion (a 7% increase year-over-year) • 2024: $2.10 billion. why ALMS is not worth anything? weird

$ALMS macro events pulling whole biotech sector, except a few names, down- the war, gas prices, the hornet’s nest this current president has stirred up creates buying or shorting opportunities/ sucks for small biotechs trying to bring much needed drugs and services to the market. Hopefully 2028 US elections give American voters more stable, thoughtful, experienced candidates to choose from- the choices in 2024 were both bad- the one that seemed the better choice turned out to be all about war, personal enrichment, insider trading and price inflation- oh well. Hopefully this company does well longer term…

$ALMS boy that is one ugly chart. I don't quite understand why the stock is behaving this way, the bad news was way overdone. I have seen stocks like this stay at the lows, even make new lows, for a very long time and never recover. This seems to be the case here.

$ALMS New to this ticker guys, why did it drop 57%? Was there more nuance to missing the target? Appreciate any input.